- Joined
- Sep 2, 2024
- Messages
- 506
- Reaction score
- 1,220
Below are some hyperlinked articles without pay walls on retatrutide. The article by Jastreboff, et al., describes a 48-week, phase 2 trial of reta.
Abdul-Rahman, et al., The power of three - Retatrutide's role in modern obesity and diabetes therapy (2024) 985 Europ. J. Pharmacol. 177095, https://doi.org/10.1016/j.ejphar.2024.177095.
Alfaris, et al. (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity - a narrative review. EClinicalMedicine, 75, 102782. doi.org/10.1016/j.eclinm.2024.10.
Bailey, et al. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides 173, 171149, doi.org/10.1016/j.peptides.2024.171149.
Brzozowska, et al. (2024). Retatrutide-revolutionary recently developed GLP agonist-literature review. Quality in Sport, 15, 52125-52125, doi.org/10.12775/qs.2024.15.52125.
Deravi, et al., The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity (2024) 40(6) J. Pharm. Technol. 300, doi: 10.1177/87551225241285326.
Gutgesell , et al. (2024). Dual and Triple Incretin-Based Co-agonists - Novel Therapeutics for Obesity and Diabetes (2024) Diabetes Therapy, 15, 1069–1084, doi.org/10.1007/s13300-024-01566-x .
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972.
Kaur & Misra (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669-676, doi.org/10.1007/s00228-024-03646-0, PMID: 38367045.
Le Roux & Mondoh (2024). Treatment of obesity with medications binding the glucagon-like peptide 1 receptor - what is the current state of play[Q] Expert Opinion on Pharmacotherapy, 25(2), 131-138, DOI: 10.1080/14656566.2024.2311731.
Martins, et al. (2024). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus. Exploration Drug Sci., 2, 126-143, doi.org/10.37349/eds.2024.00039.
Moiz, et al. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-01590.
Otvos (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 19(8), 869-872, DOI:10.1080/17460441.2024.2365969.
Pasqualotto, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers - A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 24, 100321. https://doi.org/10.1016/j.metop.2024.100321.
Rosenstock, et al., Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes - a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
conducted in the USA (2023) The Lancet, 402(10401), 529–544. https://doi.org/10.1016/s0140-6736(23)01053-x.
Ruder, At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide (2024) 331(1) JAMA 9, https://doi.org/10.1001/jama.2023.23141.
Sanyal, et al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease - a randomized phase 2a trial (2024) 30 Nature Medicine 2037, doi:10.1038/s41591-024-03018-2.
Sutherby, It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way (Jun. 3, 2024) 34(6) Managed Healthcare Executive.
Tetelbaun, et al., The First Triple Agonist for Antiobesity - Retatrutide (pre-publication, 2024) Cardiology in Review. https://doi.org/10.1097/crd.0000000000000793.
Urva, et al., LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes - a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022) 400(10366 Lancet 1869, doi: 10.1016/S0140-6736(22)02033-5.
2024-01-10: Edited to include several more sources.
Abdul-Rahman, et al., The power of three - Retatrutide's role in modern obesity and diabetes therapy (2024) 985 Europ. J. Pharmacol. 177095, https://doi.org/10.1016/j.ejphar.2024.177095.
Alfaris, et al. (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity - a narrative review. EClinicalMedicine, 75, 102782. doi.org/10.1016/j.eclinm.2024.10.
Bailey, et al. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides 173, 171149, doi.org/10.1016/j.peptides.2024.171149.
Brzozowska, et al. (2024). Retatrutide-revolutionary recently developed GLP agonist-literature review. Quality in Sport, 15, 52125-52125, doi.org/10.12775/qs.2024.15.52125.
Deravi, et al., The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity (2024) 40(6) J. Pharm. Technol. 300, doi: 10.1177/87551225241285326.
Gutgesell , et al. (2024). Dual and Triple Incretin-Based Co-agonists - Novel Therapeutics for Obesity and Diabetes (2024) Diabetes Therapy, 15, 1069–1084, doi.org/10.1007/s13300-024-01566-x .
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972.
Kaur & Misra (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669-676, doi.org/10.1007/s00228-024-03646-0, PMID: 38367045.
Le Roux & Mondoh (2024). Treatment of obesity with medications binding the glucagon-like peptide 1 receptor - what is the current state of play[Q] Expert Opinion on Pharmacotherapy, 25(2), 131-138, DOI: 10.1080/14656566.2024.2311731.
Martins, et al. (2024). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus. Exploration Drug Sci., 2, 126-143, doi.org/10.37349/eds.2024.00039.
Moiz, et al. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-01590.
Otvos (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 19(8), 869-872, DOI:10.1080/17460441.2024.2365969.
Pasqualotto, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers - A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 24, 100321. https://doi.org/10.1016/j.metop.2024.100321.
Rosenstock, et al., Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes - a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
conducted in the USA (2023) The Lancet, 402(10401), 529–544. https://doi.org/10.1016/s0140-6736(23)01053-x.
Ruder, At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide (2024) 331(1) JAMA 9, https://doi.org/10.1001/jama.2023.23141.
Sanyal, et al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease - a randomized phase 2a trial (2024) 30 Nature Medicine 2037, doi:10.1038/s41591-024-03018-2.
Sutherby, It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way (Jun. 3, 2024) 34(6) Managed Healthcare Executive.
Tetelbaun, et al., The First Triple Agonist for Antiobesity - Retatrutide (pre-publication, 2024) Cardiology in Review. https://doi.org/10.1097/crd.0000000000000793.
Urva, et al., LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes - a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022) 400(10366 Lancet 1869, doi: 10.1016/S0140-6736(22)02033-5.
2024-01-10: Edited to include several more sources.
Last edited:
